Citadel Advisors
NRIX icon

Citadel Advisors’s Nurix Therapeutics NRIX Stock Holding History

Citadel Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$277K Buy
+11,400
New +$194K ﹤0.01% 11307
2025
Q4 		– Sell
-11,300
Closed -$104K – 13632
2025
Q3 		$104K Hold
11,300
– – ﹤0.01% 11829
2025
Q2 		$129K Buy
11,300
+3,400
+43% +$36.7K ﹤0.01% 11102
2025
Q1 		$93.9K Sell
7,900
-1,800
-19% -$30.1K ﹤0.01% 11562
2024
Q4 		$183K Sell
9,700
-700
-7% -$16K ﹤0.01% 10592
2024
Q3 		$234K Sell
10,400
-25,700
-71% -$582K ﹤0.01% 9834
2024
Q2 		$753K Buy
36,100
+31,800
+740% +$495K ﹤0.01% 7186
2024
Q1 		$63.2K Sell
4,300
-1,600
-27% -$17.2K ﹤0.01% 11939
2023
Q4 		$60.9K Sell
5,900
-5,300
-47% -$36.3K ﹤0.01% 11577
2023
Q3 		$88K Sell
11,200
-1,100
-9% -$10K ﹤0.01% 11051
2023
Q2 		$123K Buy
12,300
+10,200
+486% +$104K ﹤0.01% 10615
2023
Q1 		$18.6K Buy
2,100
+1,600
+320% +$16.7K ﹤0.01% 13116
2022
Q4 		$5.49K Buy
+500
New +$6.03K ﹤0.01% 13992

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors's NRIX Position: Q2 2026 in Review

Citadel Advisors increased its Nurix Therapeutics (NRIX) stake by 9.9% in Q2 2026, buying an estimated $2.27M and bringing the position to 1,477,019 shares worth $35.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1903.

Citadel Advisors first reported a position in NRIX in Q3 2020 and has held it in 22 quarters since. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Citadel Advisors held 1,477,019 shares of Nurix Therapeutics worth $35.8M as of Q2 2026.
  • Citadel Advisors bought 133,319 Nurix Therapeutics shares in Q2 2026, an estimated $2.27M.
  • Nurix Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #1903 holding.
  • Citadel Advisors first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 22 quarters since.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.